W
WAVEMAN · COMPANY
IBO · Impact Biomedical Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

IBO

IMPACT BIOMEDICAL INC.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001834105
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-$57.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
6
13F, latest reported quarter
REVENUE GROWTH
-36.0%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$57.8K over 180 days
more than 58% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
6 funds added or opened last quarter
below 92% of Pharma & Biotech
REVENUE
-36.0% year over year
below 79% of Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
0.5% of shares outstanding short · 27.1 days to cover · settled 2026-07-31
below 78% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -20.0%
-20.0%12M
-33%-12%+9%+30%2025-092025-102025-122026-032026-052026-072026-09 2026-03-23 · Grady Jason sold $32.5K2026-03-27 · Macko Todd D sold $24.3K2026-03-25 · Macko Todd D sold $960
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $57.8K sold by insiders over 180 days, 6 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, IMPACT BIOMEDICAL INC. insiders sold a net $57.8K of stock across 37 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Macko Todd D
Chief Financial Officer
SELL
2026-03-27
43,400.0
$24.3K
Macko Todd D
Chief Financial Officer
SELL
2026-03-25
1,600.0
$960
Grady Jason
Director
SELL
2026-03-23
50,000.0
$32.5K
DSS, INC.
SELL
2025-05-27
45,400.0
$24.5K
DSS, INC.
SELL
2025-05-27
45,400.0
$24.5K
37 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 32 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
GEODE CAPITAL MANAGEMENT, LLC
1,185,163.0 sh
$545.6K
VANGUARD CAPITAL MANAGEMENT LLC
808,689.0 sh
$372.0K
STATE STREET CORP
607,897.0 sh
$279.6K
VANGUARD FIDUCIARY TRUST CO
589,428.0 sh
$271.1K
BlackRock, Inc.
259,946.0 sh
$119.6K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
VANGUARD EXTENDED MARKET INDEX FUND
$424.2K POSITION · AS OF 2026-03-31
0.0%
Fidelity Extended Market Index Fund
$17.9K POSITION · AS OF 2026-02-28
0.0%
Fidelity Series Total Market Index Fund
$14.8K POSITION · AS OF 2026-02-28
0.0%
Fidelity Total Market Index Fund
$6.6K POSITION · AS OF 2026-02-28
0.0%
iShares Core S&P Total U.S. Stock Market ETF
$4 POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$32.0K$50.0K
OPERATING INCOME$-4.3M$-28.8M$-4.0M$-3.4M
NET INCOME$-11.8M$-24.7M$-4.3M$-7.3M
EPS (DILUTED)-0.38-2.30-0.07-0.10
OPERATING CASH FLOW$-1.9M$-2.9M$-2.9M$-2.2M
CASH$3.0K$2.0M$1.0K$2.0K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →